- Home
- / Pharmanutra
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pharmanutra financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€56.8
2024-10-29
Market Capitalization
€545.7 M
2024-10-29
Revenue
€115.5 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 46.7M | 53.6M | 56.4M | 68.1M | 82.7M | 100.2M | 115.5M |
| Cost of goods sold | 32.0M | 2.9M | 8.3M | 5.3M | 2.8M | 2.4M | 6.4M |
| Gross profit | 16.2M | 51.4M | 50.4M | 63.5M | 80.6M | 99.5M | 110.5M |
| Gross profit margin, % | 34.6% | 95.8% | 89.3% | 93.3% | 97.4% | 99.3% | 95.7% |
| Operating expense total | 3.6M | 38.2M | 34.9M | 43.4M | 56.2M | 73.0M | 79.5M |
| Depreciation and amortization | 661.0K | 832.0K | 934.0K | 1.0M | 1.1M | 2.4M | 3.3M |
| EBITDA | 12.6M | 13.2M | 15.6M | 20.1M | 24.4M | 26.5M | 31.0M |
| EBITDA margin, % | 26.9% | 24.6% | 27.6% | 29.5% | 29.4% | 26.4% | 26.9% |
| EBIT | 11.9M | 12.2M | 14.6M | 19.1M | 23.2M | 24.1M | 27.8M |
| EBIT margin, % | 25.5% | 22.8% | 25.9% | 28.0% | 28.1% | 24.0% | 24.1% |
| Interest income | 5.0K | 71.0K | 88.0K | 118.0K | 128.0K | 320.0K | 676.0K |
| Interest expense | 68.0K | 77.0K | 59.0K | 38.0K | 116.0K | 937.0K | 1.5M |
| Pre tax profit | 11.9M | 12.2M | 13.3M | 18.8M | 23.4M | 23.3M | 27.2M |
| Income tax expense | 3.3M | 3.7M | (770.0K) | 5.0M | 8.4M | 10.4M | 10.6M |
| Net Income | 8.6M | 8.5M | 14.1M | 13.8M | 15.0M | 12.8M | 16.6M |